BIOTECHNOLOGY UPDATE

June 16, 2018

This Whitepaper provides up-to-date information on activities related to biotechnology at the Organisation for Economic Co-operation and Development (OECD). It is mainly intended for OECD staff and delegates to OECD meetings who are already familiar with certain aspects of the Organisation’s work. We hope that it is also informative for the wider biotech community

Spotlight

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company’s live virus vaccine platform.

OTHER WHITEPAPERS
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

A digital ecosystem for Clinical Trails

whitePaper | July 30, 2021

Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.

Read More
news image

IoT To The Rescue For Biotech & Pharma Manufacturing

whitePaper | April 7, 2020

The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

Cell Lysate Sample Handling with Simoa Bead-Based Assays

whitePaper | November 12, 2019

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More

Spotlight

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company’s live virus vaccine platform.

Events